Valeant completes sale of products to Nestle for $1.4B

Valeant Pharmaceuticals ($VRX) has wrapped up its sale of a lineup of cosmetic drugs to Nestlé's Galderma for $1.4 billion. Nestlé will grab North American rights for antiwrinkle treatments Restylane, Perlane, Emervel and Dysport. The company already claims the ex-North American rights to those treatments, thanks to its March move to take full ownership of Galderma, a dermatology venture with L'Oreal. Release | More